Suraksha Diagnostic Limited Reports Strong Q1 FY27 Results; PAT Jumps 40% YoY
Kolkata, August 12, 2026: Suraksha Diagnostic Limited, described as the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended June 30, 2026. The company reported robust performance across key metrics, with Profit After Tax (PAT) growing by 40% year-on-year, while EBITDA saw a significant rise of 27.9%.The results reflected sustained growth in both operational volumes and revenue realizations during the quarter.
Q1 FY27 Financial Performance Overview
Suraksha Diagnostic Limited posted steady financial results for the quarter ended June 30, 2026 (Q1 FY27). The company's total income stood at ₹887.33 million in Q1 FY27, up from ₹734.92 million in Q1 FY26.A breakdown of the key financial highlights is provided below:
| Particulars | Q1 FY27 | Q1 FY26 | Y-o-Y | FY26 | FY25 | Y-o-Y |
|---|---|---|---|---|---|---|
| Total Income (₹ million) | 887.33 | 734.92 | 20.7% | 3135.78 | 2559.39 | 22.5% |
| EBTIDA (₹ million) | 315.30 | 246.56 | 27.9% | 985.58 | 850.88 | 15.8% |
| EBTIDA Margin (%) | 36.0% | 34.0% | 31.8% | 33.8% | ||
| PAT (₹ million) | 128.45 | 91.75 | 40.0% | 314.04 | 309.78 | 1.4% |
| PAT Margin (%) | 14.7% | 12.6% | 10.1% | 12.3% |
Operational Highlights
Operational metrics demonstrated healthy growth across the quarter, contributing to the strong financial results. Total tests increased by 8.9%, while patient count rose by 12.1%.Key operational figures for the first quarter are as follows:
| Particulars | Q1 FY27 | Q1 FY26 | Y-o-Y | FY26 | FY25 | Y-o-Y |
|---|---|---|---|---|---|---|
| Total tests (# million) | 2.10 | 1.92 | 8.9% | 8.16 | 6.68 | 22.0% |
| Total Patients (# million) | 0.38 | 0.33 | 12.1% | 1.37 | 1.19 | 14.9% |
| Tests per patient (#) | 5.56 | 5.72 | -2.8% | 5.95 | 5.60 | 6.2% |
| Average Revenue per test (₹) | 418 | 377 | 10.6% | 381 | 377 | 0.9% |
| Average Revenue per patient (₹) | 2,321 | 2,101 | 10.5% | 2,264 | 2,113 | 7.1% |
Management Commentary
Mrs. Ritu Mittal, Joint Managing Director and CEO, commented on the results, stating that Suraksha began FY27 with a strong note, reflecting healthy growth in both volumes and realizations."Revenue grew 21% YoY in Q1 FY27, with EBITDA increasing 28% and PAT growing 40%, supported by an improvement in EBITDA margin to 36.0%. The quarter witnessed healthy growth in both patient and test volumes, complemented by healthy realization growth," she said.
Mittal also highlighted the company's strategic expansion, mentioning that one hub and three spoke centres were commissioned during the quarter. She added that Suraksha Genomics showed strong trajectory, delivering revenue growth of 136% YoY in Q1 FY27, marking the fifth consecutive quarter of sequential growth.
About Suraksha Diagnostic Limited
Suraksha Diagnostic Limited is an integrated provider of solutions in pathology and radiology testing, as well as medical consultation services. The company operates across states including West Bengal, Bihar, and Assam, serving as the largest integrated diagnostic chain in East India.SURAKSHA Stock Price Movement
Suraksha Diagnostic Limited shares gained on Wednesday, with the stock closing at ₹270.35 after rising 4.43% from the previous session's close. The equity experienced robust trading, witnessing a volume of 203,580 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.